Icell Kealex Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Icell Kealex Therapeutics General Information

Description

Developer of an innovative cancer therapy intended for the treatment of solid tumors. The company is combining vaccinia virus (VV) with T-cell-based immunotherapy that can selectively infect and destroy cancer cells while sparing healthy cells, enabling healthcare professionals to a targeted tool for treating patients with cancer.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 2450 Holcombe Boulevard
  • Suite J206
  • Houston, TX 77021
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Icell Kealex Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 09-Feb-2024 Completed Out of Business
1. Accelerator/Incubator 02-Mar-2016 Completed Startup
To view Icell Kealex Therapeutics’s complete valuation and funding history, request access »

Icell Kealex Therapeutics Patents

Icell Kealex Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2019367965-A1 Mutant vaccinia viruses and use thereof Inactive 22-Oct-2018 0000000000
EP-3870217-A1 Mutant vaccinia viruses and use thereof Pending 22-Oct-2018 0000000000
EP-3870217-A4 Mutant vaccinia viruses and use thereof Pending 22-Oct-2018 0000000000 0
CA-3117378-A1 Mutant vaccinia viruses and use thereof Pending 22-Oct-2018 0000000000
US-20210388388-A1 Mutant vaccinia viruses and use thereof Pending 22-Oct-2018 C07K14/005
To view Icell Kealex Therapeutics’s complete patent history, request access »

Icell Kealex Therapeutics FAQs

  • When was Icell Kealex Therapeutics founded?

    Icell Kealex Therapeutics was founded in 2015.

  • Who is the founder of Icell Kealex Therapeutics?

    Shautong Song and Xiao-Tong Song are the founders of Icell Kealex Therapeutics.

  • Where is Icell Kealex Therapeutics headquartered?

    Icell Kealex Therapeutics is headquartered in Houston, TX.

  • What industry is Icell Kealex Therapeutics in?

    Icell Kealex Therapeutics’s primary industry is Drug Discovery.

  • Is Icell Kealex Therapeutics a private or public company?

    Icell Kealex Therapeutics is a Private company.

  • What is Icell Kealex Therapeutics’s current revenue?

    The current revenue for Icell Kealex Therapeutics is 000000.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »